



**2020 Alliance Spring Group Meeting
Multiple Myeloma Committee**
Saturday, May 16th, 2020
11am CT / 12pm ET
Dial-In Number: 800-501-8979
Access Code: 0739814

Multiple Myeloma Committee Spring Meeting Agenda

Chair: Paul Richardson, MD
Vice-Chair: Philip McCarthy, MD

I. Welcome and Introductions

II. Alliance Studies (Completed and Ongoing)

- a. A061202: Phase I/II Pom/Dex +/- Ixazomib (MLN9708) in Relapsed and Refractory MM (RR MM) – Peter Voorhees
- b. A061402: Solitary Osseous Plasmacytoma – Anuj Mahindra
- c. AFT29: Phase II RVd +/- Dara (the Griffin trial) in Newly Diagnosed (ND) MM – Peter Voorhees, Jacob Laubach, Paul Richardson
- d. CALGB 100104 Phase III and derived studies – Phil McCarthy
- e. Auto/Allo in MM (CALGB 100001; Phase I/II) - Phil McCarthy and Sarah Holstein
- f. IFM/DFCI 2009 Study (Phase III BMT CTN 1304; the Determination trial) – Paul Richardson
- g. AFT15: Phase I/II Ibrutinib + Rd in RR MM – Yvonne Efebera & Jacob Laubach

III. Alliance Studies (Activation Pending)

- a. AFT41: Phase II RID +/- Dara in non-SCT eligible ND MM – Betsy O'Donnell, Jacob Laubach, Paul Richardson, Noopur Raje

IV. Endorsed Studies

- a. ECOG – E1A11: Phase III RVd vs KRd in ND MM – Edward Faber

- b. SWOG – S1211: Phase III RVD +/- Elo for ND high risk MM – Peter Voorhees
- c. SWOG – S1304: Phase II Carfilzomib in RR MM (completed; results pending) – Peter Voorhees
- d. BMT CTN 1302: Phase II RIC Allo-SCT followed by Ixazomib maintenance in ND MM – Cristina Gasparetto
- e. SWOG – S1702: Phase II Isatuximab for previously treated AL Amyloidosis – Heather Landau & Hani Hassoun

V. New Initiatives in Process

- a. AFT35: Phase I/II PVD Dara in RR MM – Hani Hassoun, Paul Richardson
- b. A061901: Phase I/II study of Venetoclax w/ RVD + Dara in newly-diagnosed plasma cell leukemia – Peter Voorhees
- c. A061904: Maintenance after 2nd transplant with Venetoclax – Sarah Holstein and Phil McCarthy
- d. Phase II study of CyBORd-Dara in monoclonal gammopathy-associated kidney diseases – Hani Hassoun, Sasha Tuchman, Anuj Mahindra, Giada Bianchi

VI. New Proposals in Development

- a. Optimal duration of lenalidomide maintenance in MRD negative ND MM patients post ASCT – Peter Voorhees
- b. Selinexor/Carfilzomib/dex vs. Selinexor/Pom/dex in RRMM After Dara-failure – Cristina Gasparetto, Andrew Yee, Paul Richardson
- c. Relapsed, Refractory Multiple Myeloma – Treatment Strategies After CAR T Failure – Philip McCarthy
- d. Phase I/II study of AMG 701 in RRMM patients post CAR T-Cell relapse – Jens Hillengass
- e. CC220 (Iberdomide) +/- Elotuzumab (vs/+ Isatuximab, GSK 916) in Dara-Exposed RRMM – Monique Hartley-Brown, Yvonne Efebera, Philip McCarthy, Paul Richardson
- f. CAR T-Cell Therapy for Myeloma Patients with an Autoimmune Disorder – Philip McCarthy

- g. Other study proposals – Julian Sprague

VII. Correlative Science Studies

- a. A151210/ A151211: Understanding the molecular basis for myeloid B-cell transformation in the plasma cell dyscrasias and second malignancies in myeloma – Phil McCarthy
- b. Therapeutic Subcommittee for MM in Older Adults – Tanya Wildes, Sascha Tuchman, Ashley Rosko, Betsy O'Donnell

VIII. Closing Remarks and Next monthly conference call

- a. Committee TC: Friday, June 19th, 2020; 3:00-4:00pm CT / 4:00-5:00pm ET
- b. Administrative Call (Paul, Phil, Vera, Shira, Destin) Thursday, June 18th, 3:30 4:00pm CT / 4:30-5:00pm ET